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A B S T R A C T
In breast cancer, GATA3 mutations have been associated with a favorable prognosis and the response to
neoadjuvant aromatase inhibitor treatment. Therefore, we investigated whether GATA3mutations predict
the outcome of tamoxifen treatment in the advanced setting. In a retrospective study consisting of 235
hormone-naive patients with ER-positive breast cancer who received tamoxifen as ﬁrst-line treatment
for recurrent disease, GATA3 mutations (in 14.0% of patients) did not signiﬁcantly associate with either
the overall response rate (ORR) or with the length of progression-free survival (PFS) after the start of
tamoxifen therapy. Interestingly, among 148 patients for whom both mutation and mRNA expression data
were available, GATA3 mutations associated with an increased expression of GATA3. However, only 23.7%
of GATA3 high tumors had a mutation. Evaluation of the clinical signiﬁcance of GATA3 mRNA revealed
that it was associated with prolonged PFS, but not with the ORR, also in multivariate analysis. Thus, GATA3
mRNA expression, but not GATA3 mutation, is an independent predictor of prolonged PFS in ER-positive
breast cancer patients who received ﬁrst-line tamoxifen for recurrent disease. Besides GATA3 mutation,
other mechanisms must exist that underlie increased GATA3 levels.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Breast cancer is one of the most frequently diagnosed cancers
in Western women. About 70% of all diagnosed breast cancers are
estrogen receptor α (ER) positive. ER-positive breast cancers are well-
differentiated and have a better outcome compared to other subtypes
[1,2]. In this respect, tamoxifen is a frequently used and effective
drug for patients diagnosed with ER-positive disease. However, half
of ER-positive patients who receive tamoxifen as ﬁrst-line therapy
for recurrent disease do not respond to the treatment due to in-
trinsic resistance, while the other half initially responding patients
become resistant during treatment [3]. To better understand the
mechanism involved in this intrinsic and acquired resistance and
to be able to predict which patients are likely to respond to
tamoxifen, the identiﬁcation of novel markers predicting the eﬃ-
cacy of tamoxifen treatment is highly needed.
GATA3 belongs to a family of zinc-ﬁnger transcription factors and
is involved in embryogenesis and the differentiation of a variety of
human tissues, including kidney, skin, breast and the central nervous
system [4–8]. Both in the normal mammary gland and breast cancer
tissue, GATA3 and ER expression are highly correlated [6,9]. In fact,
GATA3 is expressed in the normal luminal epithelial cells where it
maintains luminal cell differentiation [7], whereas in breast cancer
GATA3 is highly expressed in the luminal subtype, regulating differ-
entiation and suppressing dissemination [7,10,11]. Furthermore, GATA3
is an integral component of the ER pathway as it regulates the pioneer
factor FOXA1 and mediates ER binding by shaping enhancer acces-
sibility [7,12]. Consequently, a large overlap exists between co-
expressed genes for ER and GATA3, including many well-known ER
pathway genes [13]. Since the expression of ER has important im-
plications for both prognosis and treatment of breast cancers, several
studies have assessed the association of GATA3with clinical outcome.
High GATA3 protein expression was shown to be associated with a
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lower grade, smaller tumor size and increased ER and PR expres-
sion [14–18]. In line with these ﬁndings, some, but not all, studies
have shown that both GATA3 mRNA and GATA3 protein expression
are independent prognostic markers, where high levels of GATA3 as-
sociate with a longer disease-free and overall survival in breast cancer
patients [14,15,18–21]. Furthermore, in a small study of Parikh et al.
high levels of GATA3 protein were predictive of hormone respon-
siveness in ER-positive breast cancer patients [22]. In the neoadjuvant
setting both GATA3mRNA and GATA3 protein expressionwere shown
to be predictive of a favorable response to chemotherapy [17,23].
The human GATA3 gene is a highly conserved gene located at
10p14-15 and consists of six exons which encode a protein of 444
residues [24]. Germlinemutations of GATA3 cause a rare and complex
disease of hypoparathyroidism, sensorineural deafness and renal in-
suﬃciency (HDR syndrome) [25]. In breast cancer, GATA3 is one of
the most frequently mutated genes [26–29] and sporadic hetero-
zygous GATA3 mutations have been identiﬁed in approximately
5–20% of ER-positive breast cancers [30]. These mutations mostly
cluster in the vicinity of the second zinc ﬁnger of GATA3 [31] and
are virtually absent among ER-negative breast cancers. Interest-
ingly, GATA3 mutations were correlated with improved disease-
free and overall survival in breast cancer patients overall, but also
in ER-positive breast cancer patients who received adjuvant endo-
crine therapy [32]. Furthermore, mutations inGATA3were also shown
to be correlated with response to neoadjuvant aromatase inhibi-
tion treatment [33]. This suggests that GATA3 mutation may be a
determinant of the response to hormonal treatment.
To investigate this hypothesis, we analyzed exons 5 and 6 of the
GATA3 gene for mutations in 235 ER-positive primary breast cancers
and evaluated the association of the identiﬁed mutations with the
ORR and PFS of ﬁrst-line tamoxifen therapy given for recurrent
disease, as well as with GATA3 mRNA expression levels.
Materials and methods
Study population
This retrospective study included 235 female breast cancer patients (Fig. 1) and
was approved by the Medical Ethical Committee of the Erasmus Medical Center Rot-
terdam, the Netherlands (MEC 02.953). In this study we adhered to the Code of
Conduct of the Federation of Medical Scientiﬁc Societies in the Netherlands
(http://www.fmwv.nl) and results are reported in accordance with the REMARK cri-
teria on clinical reporting [34]. All patients were diagnosed between 1979 and 1996
with measurable breast cancer disease, underwent primary surgery and were treated
with tamoxifen as ﬁrst-line treatment that was given for recurrent disease. Primary
tumors were ER-positive and a minimum of 100 mg of fresh frozen tissue was re-
quired for downstream DNA and RNA extraction [35]. ER and/or PR positivity was
deﬁned by ≥10 fmol/mg cytosolic protein [36,37] and ERBB2 overexpression was
deﬁned by a reverse transcriptase quantitative PCR (RT-qPCR) expression level ≥18
[38]. The patients did not receive neo-adjuvant therapy or adjuvant hormonal treat-
ment, did not experience previous other cancers and did not show subjective or
objective toxicity [35]. There were 296 patients that fulﬁlled these criteria and from
whom detailed clinical follow up and primary tumor DNA was available. However,
60 patients were excluded as the percentage of tumor cell nuclei was below 50%,
precluding reliable mutation analysis. Furthermore, mutation analysis failed in 1
patient, totaling to n = 235 included in the present study. From these, 84 patients
underwent breast-conserving lumpectomy and 151 underwent modiﬁed mastec-
tomy. In addition, 17 patients received adjuvant anthracycline-containing
chemotherapy and 14 received adjuvant chemotherapy without anthracyclines. There
were 209M0 patients and 26M1 patients. The median age at the time of the primary
surgery was 57 years, while the median age at the start of ﬁrst-line treatment was
61 years. Criteria for follow up and response to tamoxifen therapy were deﬁned by
standard International Union Against Cancer criteria of tumor response [39]. Com-
plete and partial remission (together objective response) was observed in 4 and 34
patients, respectively, whereas 52 patients had progressive disease. From the pa-
tients with stable disease, 132 had no change for longer than 6 months, whereas
13 patients had no change for ≤6 months. According to the advice of the European
Organization for Research and Treatment of Cancer [40], we deﬁned overall re-
sponse as complete and partial remission including stable disease >6 months. As a
result, 170 patients were classiﬁed as responders to tamoxifen and 65 patients showed
no response to tamoxifen. Themedian follow up of patients after the start of tamoxifen
therapy was 49 months (range: 4–208 months). At the end of the follow up, 224
patients had developed tumor progression and 196 patients had died.
From 148 of the 235 patients we had total RNA of suﬃcient quality from the
primary tumor available (i.e. at an input of 10 ng total RNA ampliﬁable for 3 refer-
ence genes within 25 cycles) in order to perform GATA3 mRNA expression analysis
by RT-qPCR. The clinicopathological variables of the patients are shown in Table 1.
Mutation analysis
Genomic DNA previously extracted from the fresh frozen primary breast tumor
of 235 patients [41] and quantiﬁed by Picogreen was used at an input of 20 ng to
amplify GATA3 exon 5 and 6 sequences. Subsequently, PCR amplicons were sub-
jected to Sanger sequencing analysis on an ABI3130XL Genetic Analyzer (Applied
Biosystems, Foster City, CA). All mutations were conﬁrmed by Sanger sequencing
using an independently ampliﬁed template. For the splice acceptor site mutations
we performed an exonic reverse transcriptase PCR (RT-PCR) on a RNA template instead
of PCR on a DNA template. We reported GATA3 mutations and predicted protein
changes according the HGVS recommendations for the description of sequence vari-
ants [42]. PCR and sequencing primer sequences are available in Table S1A and B.
Expression analysis
Total RNA was extracted and cDNA was synthesized previously from the fresh
frozen primary breast tumor of 148 patients as described before [35]. qPCR for
GATA3 was performed in a Mx3000P™ Real-Time PCR System (Agilent, Amster-
dam, the Netherlands) using SensiFast Probe Lo-Rox master mix (GC Biotech, Alphen
aan den Rijn, the Netherlands) and a Taqman Gene expression Assay kit from Applied
Biosystems (Hs00231122_m1; spanning exons 2 to 3; Nieuwerkerk aan den IJssel,
the Netherlands) with 40 rounds of ampliﬁcation as recommended by the manu-
facturer. In addition to a negative control (i.e. genomic DNA), we also included a
standard curve of a serially diluted cDNA sample consisting of pooled breast cancer
cDNA samples in each PCR plate. The latter was done to ensure that the PCR eﬃ-
ciency between plates was comparable and to normalize the data obtained from
different plates and experiments. GATA3 mRNA expression levels for the samples
were determined relative to the average Cq value of our reference gene set consist-
ing of hydroxymethylbilane synthase (HMBS), hypoxanthine phosphoribosyltransferase
1 (HPRT1) and TATA-box binding protein (TBP), and quantiﬁed as follows: GATA3
expression = 2Cq reference gene set − Cq GATA3 gene [35]. PCR primer sequences for the ref-
erence genes are available in Table S1C.
Statistical analyses
A χ2 or a Fisher’s exact test (when the expected frequency ≤5 in any of the groups)
was used to evaluate the relation between GATA3 mutation status and the clinico-
pathological variables. The relation between GATA3 mRNA expression levels and the
clinicopathological variables was evaluated using either the two-sample Wilcoxon
rank-sum test (for 2 categories) or the Kruskal–Wallis equality-of-populations rank
test (for 3 categories). The association with tamoxifen response was analyzed with
a logistic regression model to calculate odds ratios (ORs) and their 95% conﬁdence
intervals (95% CIs). PFS analysis was performed by the Kaplan–Meier method for vi-
sualization purposes and differences between survival curves were calculated by the
Peto & Peto modiﬁcation of the Gehan–Wilcoxon test (which puts more weight on
the earlier events) for GATA3 mutation status and the log-rank test for GATA3 gene
All patients
N=296 (100%)
Patients in GATA3
mutation analysis 
N=235 (79.4%)
Patients in GATA3
RT-qPCR analysis 
N=148 (50%)
ORR + PFS
Patient cohort Clinical endpoints
ORR + PFS
Exclusion criteria
DNA from tissue with 
tumor cell nuclei <50%
N=60 (20.3%)
Mutation analysis failed
N=1 (0.3%)
Total RNA not available 
or insufficient quality
N=87 (29.4%)
Fig. 1. Study design and patient subsets analyzed for GATA3 mutation status and
GATA3 mRNA expression. The “All patients (N = 296)” box represents all hormone-
naive patients diagnosed with recurrent breast cancer between 1979 and 1996 and
were treated with ﬁrst-line tamoxifen (details provided in the Materials andmethods
section). For the GATA3 mutation analysis 60 patients were excluded whose tumor
cell nuclei percentage was below 50% and mutation analysis failed in one patient.
From these 235 patients, total RNA of suﬃcient quality was available for 148 pa-
tients for GATA3 RT-qPCR analysis. Clinical endpoints were the overall response rate
(ORR) and progression-free survival (PFS).
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expression. Univariate and multivariate Cox proportional hazards regression models
were applied to calculate the hazards ratios (HRs) and 95% CIs in the analysis for
the PFS. Log2-transformed expression values for GATA3 mRNA, ER and PR protein
and ERBB2mRNAwere used in logistic and Cox regression analyses. All P-values were
two-sided and P-values smaller than 0.05 were considered to be statistically sig-
niﬁcant. Analyses were performed using R, version 3.2.3.
Results
Since at the start of this study all of the GATA3 mutations re-
ported so far clustered in exons 5 and 6 of the GATA3 gene, which
encode the highly conserved second zinc ﬁnger required for DNA
binding, we limited sequence analysis to these two exons. In total,
we identiﬁed at least one GATA3 sequence variant in 54 out of the
235 primary tumors of patients with ER-positive recurrent breast
cancer. A silentmutation in exon 5 (rs11567941; c.1257G>A; p.T122T;
minor allele frequency (MAF) = 0.02) was identiﬁed in 24 tumors;
however, we did not consider this mutation to be pathogenic. Fur-
thermore, we identiﬁed a frameshift insertion in 22 tumors, a
frameshift deletion in ﬁve tumors and a splice site deletion in six
tumors (Table 2). These mutations predicted prematurely trun-
cated proteins in 14 tumors and proteins with a longer C-terminal
tail in 19 tumors. In total, we identiﬁed 33 GATA3 mutations that
we considered to be pathogenic in 33 (14.0%) out of 235 ER-
positive primary breast tumors.
Next, we evaluated the association between GATA3 mutation
status and the clinicopathological variables (Table 1), the ORR
(Table S2) and the length of PFS after start of tamoxifen treatment
(Table S2 and Fig. 2A). We found no relation between GATA3 mu-
tation and any of the clinicopathological variables (Table 1).
Table 1
Association of GATA3 mutation status and GATA3 gene expression levels with clinicopathological variables in 235 ER-positive primary breast cancers.
Variable GATA3 mutation status GATA3 expression level
Number of wild-type
patients
Number of mutant
patients
P-value Number of
patients
Median GATA3
expressiona
P-value
Total number 202 33 148 1.224
Menopausal statusb 0.22 0.25
Premenopausal 44 11 33 0.891
Postmenopausal 157 22 115 1.238
Tumor grade 0.68 0.24
Good/Moderate 26 5 17 1.723
Poor 116 15 86 1.010
Unknown 60 13 45 1.242
Tumor size 0.057 0.41
pT1 54 4 39 1.106
pT2 + unknown 120 27 93 1.276
pT3 + pT4 28 2 16 2.053
Nodal status 0.36 0.37
N0 83 18 71 1.287
N1–3 43 7 30 1.172
N > 3 63 7 37 0.767
Unknown 13 1 10 0.778
Dominant site of relapse 0.25 0.019
Soft 24 1 13 0.276
Bone 107 17 83 1.463
Visceral 71 15 52 0.872
Disease-free interval (m) 0.53 0.42
≤12 53 8 39 1.225
13–36 78 16 64 1.144
>36 71 9 45 1.340
PR protein status 0.28 0.0015
Positive 155 22 116 1.082
Negative 46 11 32 1.646
Unknown 1 0
ERBB2 mRNA status 0.54 0.084
Positive 20 2 18 0.807
Negative 149 29 130 1.259
Unknown 33 2
a Log2-transformed GATA3 gene expression levels.
b At the start time of ﬁrst-line tamoxifen treatment; m, months.
Table 2
Identiﬁed GATA3 mutations among 235 ER-positive primary breast cancers.
Location Nucleotide change Predicted protein
change
Number of
patients
Exon 5 c.925-3_925-2delCA p.S309Pfs*45 6
Exon 5 c.961_962delTG p.C321Sfs*31 1
Exon 5 c.983_984insC p.W329Lfs*25 1
Exon 5 c.1002_1003insG p.G335Gfs*18 1
Exon 5 c.1003delG p.G335Gfs*20 1
Exon 5 c.1007_1008insC p.V341Vfs*15 1
Exon 5 c.1021_1022insC p.A341Afs*11 1
Exon 5 c.1033_1034insAC p.Y345Yfs*11 1
Exon 5 c.1035_1036insT p.Y346Lfs*7 1
Exon 6 c.1195_1196delAG p.R399Tfs*108 1
Exon 6 c.1202_1203insG p.S402Vfs*106 1
Exon 6 c.1202_1203insGTCC p.S403Vfs*106 1
Exon 6 c.1206_1207insT p.S403Ffs*105 2
Exon 6 c.1207_1208insC p.L404Pfs*103 1
Exon 6 c.1222_1223insC p.P409Afs*99 2
Exon 6 c.1223_1224insT p.P409Sfs*100 1
Exon 6 c.1223_1224insG p.P409Afs*99 1
Exon 6 c.1257_1258insC p.T421Hfs*87 1
Exon 6 c.1263_1282del20 p.M423Vfs*78 1
Exon 6 c.1271_1272insC p.P425Afs*82 2
Exon 6 c.1277_1278insA p.S427Ifs*81 2
Exon 6 c.1304_1305insC p.S437Lfs*71 2
Exon 6 c.1305delC p. S437Pfs*39 1
Nomenclature for the identiﬁed nucleotide changes and predicted protein changes
is according the HGVS recommendations for the description of sequence variants
[42].
* Stop codon.
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Furthermore, GATA3 mutations did not signiﬁcantly associate with
the ORR for tamoxifen therapy in univariate logistic regression anal-
ysis (70.8% versus 81.8%; OR = 1.86, 95% CI = 0.73–4.73, P = 0.19;
Table S2) or with the length of PFS in Kaplan–Meier (P = 0.80; Fig. 2A)
and Cox regression analysis (HR = 0.95, 95% CI = 0.65–1.40, P = 0.81;
Table S2). Also subsetting by the type of mutation (i.e. mutations
predicted to truncate versus elongate the protein) did not yield any
signiﬁcant differences. Although the number of patients was small,
survival curves appeared very similar. However, logistic regres-
sion analysis did show that the traditional predictive factor disease-
free interval was associated with the eﬃcacy of tamoxifen therapy
(Table S2). Similarly, the traditional predictive factors dominant site
of relapse, disease-free interval and the level of PR protein expres-
sion were found to be associated with PFS (Table S2). These results
implied that GATA3mutation status is not a signiﬁcant predictor for
the outcome of tamoxifen therapy in patients with recurrent disease.
Out of the 235 tumors for which we performed GATA3 muta-
tion analysis, we were able to perform GATA3 mRNA expression
analysis by RT-qPCR for 148 tumors. In 25 out of these 148 tumors
we identiﬁed a GATA3 mutation and 123 tumors were wild-type.
Interestingly, GATA3 expression levels were higher among mutant
GATA3 tumors (i.e. irrespective of the predicted effect of the mu-
tation) than wild-type GATA3 tumors (P = 0.0019). Eighteen tumors
(72.0%) with GATA3mutations had high GATA3 expression levels (i.e.
above the median) while only seven tumors (28.0%) with GATA3
mutations had low GATA3 expression levels (i.e. below the median).
However, out of the 76 GATA3 high expressing tumors, only 18
(23.7%) had a mutation in the GATA3 gene. Because the high levels
of GATA3mRNAwere only partially explained by amutation in GATA3
itself, we hypothesized that GATA3 expression instead of mutation
might be associated with the outcome of tamoxifen treatment.
To evaluate this, we made use of the GATA3 mRNA expression
data for all 148 primary breast tumors from recurrent breast cancer
patients that we had generated by RT-qPCR. We found that GATA3
expression was associated with dominant site of relapse and PR
protein status, but not with menopausal status, tumor grade, tumor
size, nodal status, disease-free interval or ERBB2 mRNA status
(Table 1). In univariate logistic regression analysis, we found no as-
sociation of GATA3 expression level with the ORR for tamoxifen
(64.9% versus 66.2%; OR = 1.12, 95% CI = 0.90–1.41, P = 0.31; Table 3).
Additionally, menopausal status, dominant site of relapse and ER
protein, PR protein and ERBB2 mRNA expression levels were also
not associated with the ORR for tamoxifen, in contrast to disease-
free interval (Table 3). GATA3 expression was, however, associated
with the length of PFS, as it was prolonged for patients with tumors
with high GATA3 mRNA levels compared to those with low levels
(P = 0.033; Fig. 2B). Concordantly, in univariate Cox regression anal-
ysis, high GATA3 expression levels were signiﬁcantly associated with
Fig. 2. Kaplan–Meier analysis of progression-free survival (A) according to GATA3mutation status for 235 ER-positive breast cancer patients who received ﬁrst-line tamoxifen
therapy for recurrent disease. The difference between the survival curves was calculated using the Peto & Peto modiﬁcation of the Gehan–Wilcoxon test. (B) Dichotomized
at median GATA3 expression level for 148 ER-positive breast cancer patients who received ﬁrst-line tamoxifen therapy for recurrent disease. The difference between the
survival curves was calculated using the log-rank test.
Table 3
Univariate logistic regression analysis of the overall response rate in 148 ER-
positive breast cancer patients treated with ﬁrst-line tamoxifen for recurrent disease.
Variable Univariate analysis
OR (95% CI) P-value
Base model:
Menopausal statusa
Premenopausal 1
Postmenopausal 1.83 (0.83–4.03) 0.13
Dominant site of relapse
Soft 1
Bone 0.43 (0.11–1.69) 0.23
Visceral 0.81 (0.20–3.40) 0.78
Disease-free interval (m)
≤12 1
13–36 4.70 (1.98–11.11) 0.00043
>36 3.54 (1.43–8.76) 0.0063
ER protein expression 1.12 (0.95–1.33) 0.17
PR protein expression 1.06 (0.95–1.18) 0.30
ERBB2 mRNA expression 1.07 (0.95–1.22) 0.26
Additions to the base model:
GATA3 mRNA expression 1.12 (0.90–1.41) 0.31
a At the start time of ﬁrst-line tamoxifen treatment; m, months.
Table 4
Univariate and multivariate Cox regression analyses of progression-free survival in
148 ER-positive breast cancer patients treated with ﬁrst-line tamoxifen for recur-
rent disease.
Variable Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Base model:
Menopausal statusa
Premenopausal 1 1
Postmenopausal 0.73 (0.49–1.09) 0.12 0.84 (0.54–1.29) 0.42
Dominant site of relapse
Soft 1 1
Bone 1.88 (0.99–3.57) 0.054 2.36 (1.21–4.63) 0.012
Visceral 1.47 (0.76–2.86) 0.26 1.74 (0.86–3.53) 0.13
Disease-free interval (m)
≤12 1 1
13–36 0.66 (0.43–0.99) 0.046 0.61 (0.40–0.93) 0.021
>36 0.56 (0.36–0.88) 0.012 0.59 (0.37–0.94) 0.026
ER protein expression 0.95 (0.87–1.03) 0.22 0.97 (0.88–1.06) 0.49
PR protein expression 0.95 (0.90–1.00) 0.051 0.95 (0.89–1.01) 0.077
ERBB2 mRNA expression 0.98 (0.91–1.05) 0.62 0.98 (0.91–1.06) 0.62
Additions to the base model:
GATA3 mRNA expression 0.87 (0.78–0.98) 0.017 0.85 (0.75–0.96) 0.0079
a At the start time of ﬁrst-line tamoxifen treatment; m, months.
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a prolonged PFS (HR = 0.87, 95% CI = 0.78–0.98, P = 0.017; Table 4).
Besides GATA3 expression levels, also disease-free interval, but not
menopausal status, dominant site of relapse and ER protein, PR
protein and ERBB2 mRNA expression levels, were associated with
the length of PFS (Table 4). In multivariate analysis, by including
GATA3 expression in a model with all the traditional predictive
factors, GATA3 expression levels were signiﬁcantly associated with
a prolonged PFS (HR = 0.85, 95% CI = 0.75–0.96, P = 0.0079; Table 4).
These results imply that GATA3mRNA expression, rather than genetic
aberration of the gene alone, is an independent predictor for the
length of PFS in hormone-naive ER-positive breast cancer patients
treated with ﬁrst-line tamoxifen for recurrent disease.
Discussion
GATA3 is one of themost frequentlymutated genes in breast cancer
[26–29] and mutations in GATA3 are associated with improved sur-
vival [32]. Because GATA3mutations are also associated with both a
favorable outcome among ER-positive patients who received adju-
vant endocrine treatment as well as response to neoadjuvant
aromatase inhibitors [32,33], we here evaluated whether GATA3mu-
tations measured in the primary tumor (i.e. all ER positive) can
determine the outcome of patients treated with ﬁrst-line tamoxifen
for recurrent disease. However, GATA3 mutations were not signiﬁ-
cantly associated with either the ORR or with PFS in 235 ER-positive
breast cancer patients who received tamoxifen as a ﬁrst-line therapy
for recurrent disease (Table S2 and Fig. 2A). Even though GATA3mu-
tations were associated with increased levels of GATA3 expression,
only GATA3 expression was found to be an independent predictor for
prolonged PFS (Table 4). Our results suggest that not GATA3 muta-
tion, but ratherGATA3 expression predicts the length of PFS. This result
will need to be validated in an independent patient population.
Jiang et al. have previously shown that GATA3 mutations were
associated with improved survival in both the TCGA cohort as well
as the Chinese FUSCC cohort [32]. In the TCGA cohort, however, this
prognostic effect was limited to ER-positive breast cancer cases
(overall survival P = 0.041) in contrast to all cases in the FUSCC cohort
(overall survival P = 0.033). Furthermore, in the FUSCC cohort, GATA3
mutations were also associated with longer disease-free survival in
ER-positive patients who received adjuvant endocrine treatment
(P = 0.046), which may suggest a role for GATA3 mutation in the ef-
ﬁcacy of endocrine therapy. However, our results do not show that
GATA3mutations are associatedwith the outcome of tamoxifen treat-
ment in 235 ER-positive patients who were treated with ﬁrst-line
tamoxifen for recurrent disease (Table S2 and Fig. 2A). This sug-
gests that the improved disease-free survival of patients with GATA3
mutated tumors in the FUSCC cohort can be attributed to a pure
prognostic association of GATA3 mutation rather than its role as a
predictive factor for tamoxifen eﬃcacy. Noteworthy, however, is that
GATA3mutations in the neoadjuvant settingwere a predictivemarker
of favorable outcome of aromatase inhibitor treatment [33]. In that
study, 77 ER-positive breast cancer samples were sequenced and
GATA3 mutations were more frequently present in aromatase in-
hibitor sensitive tumors (P = 0.01). The apparent discrepancy between
our study and the study of Ellis et al. might be attributable to a dif-
ference in the mechanism of action between aromatase inhibitors
and tamoxifen or, probably more likely, due to the difference in
primary versus recurrent disease receiving endocrine treatment and
the used endpoints.
At the gene expression level, high GATA3 has consistently and
independently of other clinicopathological predictors been linked
to a better outcome [14,19], but at the protein level the prognostic
effect of GATA3 remains controversial [15,18,20,21]. Higher sensi-
tivity and/or accuracy of gene expression compared with protein
expressionmeasurementmethods could very well explain poor con-
sistency at the protein level. Interestingly, in a small study including
only 28 patients and examining the expression of GATA3 by im-
munohistochemistry, Parikh et al. found that GATA3 expression
predicted hormone responsiveness in breast cancer as six of 14 (43%)
cancers were GATA3 negative in the hormone-unresponsive group
and 0 of 14 (0%) cancers were GATA3 negative in the hormone-
responsive group (P = 0.031) [22]. These results are in line with the
current study, where we analyzed GATA3 gene expression levels in
148 ER-positive recurrent breast cancer patients who were treated
with ﬁrst-line tamoxifen and found that high levels of GATA3 were
associated with a prolonged PFS (Fig. 2B). Moreover, in multivari-
ate analysis, GATA3 expression was an independent predictor of
progression-free survival (Table 4). The predictive effect of GATA3
at the protein level, however, requires independent examination.
In the current study, we also observed that breast cancers with
a GATA3 mutation had signiﬁcantly higher GATA3 expression levels,
although only GATA3 expression appeared to be associated with pro-
longed PFS. Importantly, from the 76 breast cancers with high GATA3
expression levels, 18 (23.7%) had a GATA3 mutation. Thus, a signif-
icant fraction (n = 58, 76.3%) of the GATA3 high breast cancers does
not have a GATA3 mutation. In order to be certain that we did not
miss any mutations located outside exons 5 and 6, we additional-
ly sequenced the other coding exons (i.e. exons 2–4) of the GATA3
gene in these 58 breast cancers, but did not ﬁnd any additional mu-
tations. This not only conﬁrms that the vast majority of GATA3
mutations are actually located in exons 5 and 6, but this also sug-
gests that there are other mechanisms besides GATA3mutation that
may be responsible for the high GATA3 expression in ER-positive
breast cancers with a wild-type GATA3 gene. As the GATA3 tran-
scription factor reshapes gene loci by recruiting chromatin
remodeling complexes, mutations of these proteins present in these
complexes or other upstream pathway members could very well
be involved in these mechanisms. For example, GATA3 expression
was recently also reported to be increased byWnt/β-catenin pathway
activation in adipocytes [43]. Identiﬁcation of these players may lead
to a better understanding of the mechanisms of resistance to
tamoxifen treatment by transcriptional regulation through GATA3,
the crucial transcription factor regulating luminal differentiation in
the mammary gland.
In conclusion, not GATA3 mutation, but GATA3 gene expression
is associated with prolonged PFS in ER-positive breast cancer pa-
tients who received ﬁrst-line tamoxifen treatment for recurrent
disease. In addition, GATA3 mutation leads to an increased GATA3
mRNA expression, but besides genetic aberration of GATA3, other
mechanisms are in place to explain the increased GATA3 levels in
GATA3 wild-type tumors with high GATA3 mRNA.
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